CDKN2A and neoplasm: A recent report has documented that cyclin dependent kinase inhibitor 2A (CDKN2A) in GBM governs the sequestration of oxidizable PUFAs into triacylglycerides (TAGs) within lipid droplets and alters the acyl tail composition in fatty acids, enabling tumor cells more tolerant to lipid peroxidation99.